'מערכת אימד'- Abstract
To investigate the effectiveness, safety, and tolerability of vortioxetine in patients treated at therapeutic doses (5–20 mg/day) for both acute and maintenance treatment, patient-level data were pooled from 5 long-term (52-week), open-label extension studies of major depressive disorder.
Eduard Vieta, Henrik Loft, Ioana Florea,
Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder,
European Neuropsychopharmacology, Volume 27, Issue 9, 2017, Pages 877-884, ISSN 0924-977X,
https://doi.org/10.1016/j.euroneuro.2017.06.012.
Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder,
European Neuropsychopharmacology, Volume 27, Issue 9, 2017, Pages 877-884, ISSN 0924-977X,
https://doi.org/10.1016/j.euroneuro.2017.06.012.